Optimizing Therapeutic Strategies in Castration-Resistant Prostate Ca…
Treatment and trials in non-metastatic castration-resistant prostate cancer | Nature Reviews Urology
Managing Castrate- Resistant Metastatic Prostate Cancer Elisabeth I. Heath, MD Associate Professor of Medicine and Oncology Wayne State University/Karmanos. - ppt download
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group - The Lancet Oncology
Advanced Prostate Cancer: Treatment Advances and Future Directions: Trends in Cancer
Figure 1 from Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. | Semantic Scholar
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial | Nature Medicine
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial - ScienceDirect
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Journal of Clinical Oncology
Prostate Cancer Working Group Updates CRPC Clinical Trial Guidelines - Cancer Therapy Advisor
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary - Urology
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study - The Lancet Oncology
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Journal of Clinical Oncology
Prostate cancer clinical states model; framework for patient management... | Download Scientific Diagram
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Journal of Clinical Oncology
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer | NEJM
AUA 2020: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer in TITAN: Prognostic Importance of Prostate-Specific Antigen Responses
The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial - The Lancet
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer | Scientific Reports
The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3
PDF) Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
Chemotherapy in Prostate Cancer- When, Why and How
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz
Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer - European Urology Focus
ESMO 2021: Apalutamide Efficacy and Safety in Asian Patients with Metastatic Castration-Sensitive Prostate Cancer
